From: COMPare: a prospective cohort study correcting and monitoring 58 misreported trials in real time
Journal name | Annals | BMJ | JAMA | Lancet | NEJM | Total | |
---|---|---|---|---|---|---|---|
Basic information | Number of trials included | 5 | 3 | 13 | 24 | 22 | 67 |
Journal listed as “endorsing CONSORT” | Yes | Yes | Yes | Yes | Yes | All | |
Protocol availability | Pre-trial protocol with pre-specified outcomes available? | 0 | 0 | 7 | 3 | 19 | 29 |
Percentage of pre-trial protocols available | 0.0% | 0.0% | 53.9% | 12.5% | 86.4% | 43.3% | |
Missing primary outcomes | Trials with any unreported primary outcomes | 4 | 2 | 2 | 4 | 1 | 13 |
Percentage of trials with any unreported primary outcomes | 80.0% | 66.7% | 15.4% | 16.7% | 5.0% | 19.4% | |
Primary outcomes | Total number of primary outcomes pre-specified | 9 | 4 | 22 | 34 | 28 | 97 |
Number of primary outcomes correctly reported as primary outcomes | 4 | 1 | 18 | 24 | 27 | 74 | |
Percentage of primary outcomes correctly reported | 44.4% | 25.0% | 81.8% | 70.6% | 96.4% | 76.3% | |
Number of primary outcomes reported anywhere | 7 | 1 | 18 | 24 | 28 | 78 | |
Percentage of primary outcomes reported anywhere | 77.8% | 25.0% | 81.8% | 70.6% | 100.0% | 80.4% | |
Secondary outcomes | Total number of secondary outcomes pre-specified | 49 | 36 | 111 | 218 | 404 | 818 |
Number of secondary outcomes correctly reported as secondary outcomes | 15 | 26 | 78 | 141 | 190 | 450 | |
Percentage of secondary outcomes correctly reported | 30.6% | 72.2% | 70.3% | 64.7% | 47.0% | 55.0% | |
Number of secondary outcomes reported anywhere | 15 | 26 | 78 | 142 | 190 | 451 | |
Percentage of secondary outcomes reported anywhere | 30.6% | 72.2% | 70.2% | 65.1% | 47.0% | 55.1% | |
Novel outcomes | Number of novel outcomes reported without declaration | 32 | 25 | 53 | 192 | 63 | 365 |
Mean number of novel outcomes reported without declaration, per trial | 6.4 | 8.3 | 4.1 | 8 | 2.9 | 5.4 (95% CI 1.2–10.6) | |
Percentage of novel outcomes declared as novel | 5.9% | 0% | 39.1% | 9.4% | 3.1% | 13.7% (95% CI 0.0–42.5%) |